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background:  Cystatin C is an early marker of renal dysfunction which is associated with mortality and cardiovascular risk. We evaluated 
the association of cystatin C with all-cause and cardiovascular mortalites in patients without chronic kidney disease (CKD) undergoing 
percutaneous coronary intervention (PCI).
methods and results:  From April 2008 to September 2012, cystatin C was measured in 1810 patients undergoing PCI (mean age 67 
years; men, 79%) whose estimated glomerular filtration rate based on creatinine was ≥60 ml/min/1.73m2. During a median follow up of 32 
months, 118 patients died including 29 cardiovascular deaths. Multivariable Cox analysis after adjustment for several confounders showed 
that cystatin C was an independent predictor of all-cause death (for each increment of 0.1 mg/dl; hazard ratio [HR], 1.19; 95% confidence 
interval [CI], 1.08-1.31; p<0.001). In the receiver-operating characteristic curve of cystatin C, the area under the curve was 0.643 (95% CI, 
0.59-0.70) for all-cause death and 0.614 (95% CI, 0.524-0.704) for cardiovascular death. For both kinds of death, the cutoff point was 0.93 
mg/l. Cystatin C ≥0.93 had an increased risk for both all-cause death (HR, 2.47; 95% CI, 1.59-3.84; p<0.001) and cardiovascular death 
(HR, 3.99; 95 % CI, 1.56-10.21; p=0.004).
Conclusion:  Cystatin C predicts all-cause and cardiovascular mortalities even in patients without CKD undergoing PCI.
